טוען...

Regression of brain metastases from breast cancer with eribulin: a case report

BACKGROUND: Eribulin is a recently approved new therapeutic option for patients with metastatic breast cancer. According to several reports, eribulin has limited ability to cross the blood brain barrier. Recently, capecitabine and eribulin have been recognized as drugs with similar application for p...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Matsuoka, Hiromichi, Tsurutani, Junji, Tanizaki, Junko, Iwasa, Tsutomu, Komoike, Yoshifumi, Koyama, Atsuko, Nakagawa, Kazuhiko
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2013
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3878316/
https://ncbi.nlm.nih.gov/pubmed/24350786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-6-541
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!